(XHS) S&P Health Care - Overview
Exchange: NYSE ARCA •
Country: USA •
Currency: USD •
Type: Etf •
ISIN: US78464A5737
Etf: Hospital, Pharmacy, Diagnostics, Insurance
Total Rating 21
Risk 48
Buy Signal -0.42
Dividends
| Dividend Yield | 0.29% |
| Yield on Cost 5y | 0.27% |
| Yield CAGR 5y | 8.40% |
| Payout Consistency | 74.0% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 19.2% |
| Relative Tail Risk | -2.63% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.24 |
| Alpha | -6.66 |
| Character TTM | |
|---|---|
| Beta | 0.567 |
| Beta Downside | 0.499 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.81% |
| CAGR/Max DD | 0.30 |
Description: XHS S&P Health Care January 05, 2026
The SPDR® S&P Health Care Services ETF (ticker XHS) aims to replicate the S&P Health Care Services Select Industry Index by using a sampling approach; it invests at least 80 % of its assets in the index’s constituents, typically covering the full basket.
Key fund characteristics (as of early 2026):
- Expense ratio: 0.15 % (below the average for U.S. health-care ETFs, which sits near 0.20 %).
- Assets under management: roughly $1.3 billion, indicating solid investor interest but still enough liquidity for efficient trading.
- Top holdings: UnitedHealth Group, CVS Health, Cigna, Humana and Teladoc Health, together accounting for about 45 % of the portfolio.
Sector drivers that underpin XHS’s performance:
- Demographic aging – the U.S. population aged 65+ is projected to grow from 16 % in 2024 to 22 % by 2035, boosting demand for managed-care and outpatient services.
- Policy environment – recent Medicare Advantage enrollment growth (≈ 8 % YoY) and potential reimbursement reforms directly affect the earnings of the fund’s largest constituents.
- Technology adoption – telehealth utilization, now stabilized at roughly 30 % of pre-pandemic in-person visits, continues to improve operational efficiency and expand service reach.
For a deeper dive into XHS’s valuation metrics and risk profile, you might find ValueRay’s analytical tools useful.
What is the price of XHS shares?
As of February 08, 2026, the stock is trading at USD 106.27 with a total of 3,946 shares traded.
Over the past week, the price has changed by -0.55%, over one month by -4.83%, over three months by +3.20% and over the past year by +7.13%.
Over the past week, the price has changed by -0.55%, over one month by -4.83%, over three months by +3.20% and over the past year by +7.13%.
Is XHS a buy, sell or hold?
S&P Health Care has no consensus analysts rating.
What are the forecasts/targets for the XHS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 107.3 | 1% |
XHS Fundamental Data Overview February 04, 2026
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 101.2m USD (101.2m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 101.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 101.2m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.01% (E(101.2m)/V(101.2m) * Re(8.01%) + (debt-free company))
Discount Rate = 8.01% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 101.2m USD (101.2m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 101.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 101.2m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.01% (E(101.2m)/V(101.2m) * Re(8.01%) + (debt-free company))
Discount Rate = 8.01% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)